News articles about AC Immune (NASDAQ:ACIU) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AC Immune earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.2421628949316 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities analysts have commented on the stock. BidaskClub lowered shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Wednesday, February 14th. Credit Suisse Group lowered shares of AC Immune from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $14.00 in a research report on Friday, March 23rd. HC Wainwright assumed coverage on shares of AC Immune in a research report on Thursday, April 5th. They issued a “buy” rating and a $18.00 price target on the stock. ValuEngine upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $14.00.
Shares of AC Immune traded up $10.06, reaching $10.06, during trading hours on Thursday, Marketbeat Ratings reports. 5,600 shares of the company were exchanged, compared to its average volume of 54,432. AC Immune has a fifty-two week low of $9.99 and a fifty-two week high of $10.00. The firm has a market capitalization of $581.98 million, a price-to-earnings ratio of -33.53 and a beta of 2.17.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.